Polyaminoacid nanocapsules for drug delivery to the lymphatic system: Effect of the particle size

Abellan-Pose, Raquel; Teijeiro-Valiño, Carmen; Santander-Ortega, Manuel J.; Borrajo, Erea; Vidal, Anxo; García-Fuentes, Marcos; Csaba, Nœmi; Alonso, Marı́a José

doi:10.1016/j.ijpharm.2016.05.034

Cited by 56 publications

(31 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings also suggest that studies on lymphatic targeting and migration of anticancer drugs are crucial, and, in fact, researchers have studied a number of targeting strategies and benefits based on the structural and physiological characteristics of the lymphatic system related to drug delivery [ 6 , 7 , 8 , 9 ]. Researchers have also reported on improving bioavailability and efficacy through formulations of conventional drugs [ 10 , 11 , 12 , 13 ]. Formulation with polyaminoacid nanocapsule has been attempted to improve lymphatic delivery of docetaxel as an anticancer drug [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Enhanced Lymphatic Delivery of Methotrexate Using W/O/W Nanoemulsion: In Vitro Characterization and Pharmacokinetic Study

2020

View full text Add to dashboard Cite

Methotrexate, which is widely used in the treatment of cancer and immune-related diseases, has limitations in use because of its low bioavailability, short half-life, and tissue toxicity. Thus, in this study, a nano-sized water-in-oil-in-water (W/O/W) double emulsion containing methotrexate was prepared to enhance its lymphatic delivery and bioavailability. Based on the results from solubility testing and a pseudo-ternary diagram study, olive oil as the oil, Labrasol as a surfactant, and ethanol as a co-surfactant, were selected as the optimal components for the nanoemulsion. The prepared nanoemulsion was evaluated for size, zeta potential, encapsulation efficiency, pH, morphology, and in vitro release profiles. Furthermore, pharmacokinetics and lymphatic targeting efficiency were assessed after oral and intravenous administration of methotrexate-loaded nanoemulsion to rats. Mean droplet size, zeta potential, encapsulation efficiency, and pH of formulated nanoemulsion were 173.77 ± 5.76 nm, −35.63 ± 0.78 mV, 90.37 ± 0.96%, and 4.07 ± 0.03, respectively. In vitro release profile of the formulation indicated a higher dissolution and faster rate of methotrexate than that of free drug. The prepared nanoemulsion showed significant increases in maximum plasma concentration, area under the plasma concentration-time curve, half-life, oral bioavailability, and lymphatic targeting efficiency in both oral and intravenous administration. Therefore, our research proposes a methotrexate-loaded nanoemulsion as a good candidate for enhancing targeted lymphatic delivery of methotrexate.

show abstract

Section: Introductionmentioning

confidence: 99%

Enhanced Lymphatic Delivery of Methotrexate Using W/O/W Nanoemulsion: In Vitro Characterization and Pharmacokinetic Study

2020

View full text Add to dashboard Cite

show abstract

“…53,54 Previous studies by our research group showed that the dilution of Miglyol 812 and lecithin in the organic phase, and the dropwise addition of this phase over an aqueous one lead to a significant decrease in the average size of the obtained oily nanodroplets, from 200 to 100 nm. 55 Based on this result, we adopted an experimental design in which we kept constant the mass and ratio of the NCs components, and we varied the following parameters: (a) the volume of the organic phase (ethanol), (b) the volume of the aqueous phase, and (c) the way the organic phase was added over the aqueous phase (pouring vs. injecting). As a standard NC composition, we chose one previously reported by our group that consisted on a combination of CS and vitamin E with lecithin as a surfactant.…”

Section: Resultsmentioning

confidence: 99%

Engineering, on‐demand manufacturing, and scaling‐up of polymeric nanocapsules

Crecente‐Campo

Alonso

2018

Bioengineering & Transla Med

Self Cite

View full text Add to dashboard Cite

Polymeric nanocapsules are versatile delivery systems with the capacity to load lipophilic drugs in their oily nucleus and hydrophilic drugs in their polymeric shell. The objective of this work was to expand the technological possibilities to prepare customized nanocapsules. First, we adapted the solvent displacement technique to modulate the particle size of the resulting nanocapsules in the 50–500 nm range. We also produced nanosystems with a shell made of one or multiple polymer layers i.e. chitosan, dextran sulphate, hyaluronate, chondroitin sulphate, and alginate. In addition, we identified the conditions to translate the process into a miniaturized high‐throughput tailor‐made fabrication that enables massive screening of formulations. Finally, the production of the nanocapsules was scaled‐up both in a batch production, and also using microfluidics. The versatility of the properties of these nanocapsules and their fabrication technologies is expected to propel their advance from bench to clinic.

show abstract

“…As an alternative, the monobodies may be able to increase tissue permeability and clearance time, thereby reducing background noises and allowing early imaging. Moreover, the small monobody can be e ciently packed into nanocapsule and potentially delivered to target cells, eventually allowing intracellular tracing of endogenous antigens (Abellan-Pose et al, 2016;Wen et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

Development of high affinity monobodies recognizing SARS-CoV-2 antigen

Zhang

Meng

et al. 2020

Preprint

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a threat to global public health. Prompt patient identification and quarantine is the most effective way to control its rapid transmission, which can be facilitated by early detection of viral antigens. Here we present a platform to develop and optimize the fibronectin-based affinity-enhanced antibody mimetics (monobodies) for recognizing viral antigens. Specifically, we developed monobodies targeting SARS-CoV-2 nucleocapsid (N) protein. We showed that two monobodies, NN2 and NC2, bind to N protein’s N- and C-terminal domains respectively with a Kd in nM range.The specificity of the recognition was confirmed with co-immunoprecipitation and immunofluorescence assays. Furthermore, we demonstrated that one round of in vitro maturation using mRNA display can improve the binding affinity of monobodies. Machine learning algorithms were integrated with deep sequencing data for selecting candidates that improve the detection sensitivity of N. Using this pair of monobodies, we have developed an enzyme-linked immunosorbent assay (ELISA) for viral detection. We were able to detect recombinant N at 4 pg/ml and detect N in viral culture supernatant, with no cross-reactivity with other CoV. Integrating high-dense mutagenesis, mRNA display, deep sequencing and machine learning, this platform can be applied through iterations to identify and optimize monobodies against emerging viral antigens, potentiating point-of-care detection of communicable diseases in a cost-and time-sensitive manner.Authors Yushen Du, Tian-hao Zhang, Xiangzhi Meng, Yuan Shi, and Menglong Hu contributed equally to this work.

show abstract

Polyaminoacid nanocapsules for drug delivery to the lymphatic system: Effect of the particle size

Cited by 56 publications

References 41 publications

Enhanced Lymphatic Delivery of Methotrexate Using W/O/W Nanoemulsion: In Vitro Characterization and Pharmacokinetic Study

Enhanced Lymphatic Delivery of Methotrexate Using W/O/W Nanoemulsion: In Vitro Characterization and Pharmacokinetic Study

Engineering, on‐demand manufacturing, and scaling‐up of polymeric nanocapsules

Development of high affinity monobodies recognizing SARS-CoV-2 antigen

Contact Info

Product

Resources

About